Mutations in the adenomatous polyposis coli (APC) gene cause the hereditary cancer syndrome familial adenomatous polyposis and are implicated in the early stages of sporadic colorectal carcinogenesis. APC is therefore a promising candidate for use in prophylactic gene therapy of intestinal tissues at high risk of becoming malignant. The aim ofthe study was to discover if functional full length APC gene can be introduced into somatic gut epithelial cells and to define the optimum conditions for such transfer.
Reverse transcriptase polymerase chain reaction (RT PCR) and restriction enzyme digest Extraction and purification of mRNA was performed using standard methods (QuickPrep Micro mRNA Purification Kit, Pharmacia). The mRNA was initially converted to cDNA (First-Strand cDNA Synthesis Kit, Pharmacia) prior to amplification by the PCR with Taq polymerase (Perkin-Elmer Cetus). Amplification of a 117 base pair fragment from nucleotides 3985 to 4102 was performed using the primers 5'GTTCCAGCAGTGTCACAG 3' and 5'GGGAGATTTCGCTCCTGA 3'. This fragment contains a PstI site at codon 1338, which divides the amplified region into 47 and 70 base pair fragments. This PstI site is present in the plasmid containing APC cDNA and in the CaCO2 cell line, which has the normal sequence across this region of its APC gene. This site has been lost in the SW480 cells, distinguishing between normal and abnormal sequences on the basis of a restriction enzyme digest. Both normal APC sequence and SW480 cells have a Hinfl site at codon 1345, which divides the amplified 117 base pair region into 67 and 50 base pair fragments. This HinfI site provided an internal control on the digestion reaction. Amplified PCR products from transfected cells were digested with both Hinfi and PstI (New England Biolabs) by incubation at 37°C for one hour. A sample of mRNA was treated in an identical manner to the other mRNA samples, but no reverse transcriptase was added to provide a control for contaminating DNA sequences.
Results Figure 1 shows that normal and mutated APC gene expression can be distinguished using RT PCR and restriction enzyme digestion. The no RT control (Fig 1, lane 1) (Fig 1, lanes 2-5) , whereas untreated SW480 cells express a mutated form of APC, which loses the PstI site at codon 1338 and produces a changed restriction enzyme digest pattern as shown (Fig 1,   lanes 6-9) .
Following lipofection of SW480 cells with APC plasmid DNA, cells were harvested at intervals from 24 hours and mRNA extraction, RT PCR, and restriction enzyme digestions performed. Transfected SW480 cells predominantly express the normal sequence APC gene at 24 (data not shown) and 48 hours after transfection (Fig 2, lanes 1-8) while higher concentrations were toxic to the cells. Reducing the time of contact between epithelial cells and the plasmid-liposome complexes from five to four hours produced similar patterns of uptake and expression. However, shorter times of exposure (three hours or less) resulted in negligible expression of the transfected gene (data not shown). All the results shown were reproducible under the same strictly controlled conditions on between four and 10 independent occasions at each time point. No change in the morphology of the transfected cells was seen at any stage.
Discussion
The treatment of severe single gene disorders by the introduction of normal genes into somatic cells is progressing to the stage of clinical trials. In cancer, gene therapy to date has focused on the introduction of genes that either kill tumour cells directly or introduce a gene producing an enzyme that metabolises a prodrug into a lethal product. [16] [17] [18] The major problem in these approaches is that tumour cells must be preferentially targeted compared with normal cells, and every tumour cell must take up the transgene (in the absence of bystander effects). These requirements are similar to the problems for chemotherapy or radiotherapy.
There have been important steps forward in elucidating the genetic basis of colorectal carcinogenesis.6 19 carries the risk of insertional mutagenesis, which may not be considered a major problem in a patient with a disseminated malignancy but could pose a significant risk to a young person undergoing prophylactic gene therapy. There is also a size limit of a few kilobases on the amount of DNA that can be handled by such vectors. Although adenoviruses are not as limited as retroviruses in the size of gene that can be integrated, there is some evidence that the virus may cause inflammation. 26 Liposomes are the only available vehicles that can safely transport large sequences of DNA such as the APC gene into cells but they are inefficient in gene delivery and short lived in effect because the DNA enters the endosomes when it is taken up by the cell.
This study has shown that full length normal APC cDNA complexed with liposomes can be introduced into a colonic epithelial cell line. The transfected sequence is expressed as mRNA at high levels from 24 to 72 hours after treatment, followed by a gradual decline in expression of the transgene. By one week only endogenous gene expression can be shown by RT PCR. Changing the amount of DNA transfected did not change the level or duration of expression, indicating that the amount of DNA/liposome complexes is not the limiting factor in persistence of transgene expression. The functional significance of the normal APC gene expression that occurs from the transgene remains to be evaluated. This will require the development of surrogate end points for APC gene expression in colonic epithelium and of normal cell lines in which function can be assessed, as well as the introduction of single copies of the APC gene under normal cellular controls.
With specific regard to FAP, there are two clinical situations in which gene therapy would be a useful preventative strategy even though 1 00% efficiency of cell targeting is not yet feasible. Patients after colectomy with an ileorectal anastomosis have an at risk rectal stump, and all patients are at risk of duodenal polyposis progressing to carcinoma for which no effective treatment is currently offered. Topical treatment with aspirin or suldinac, usually under the auspices of a clinical trial, is being used in such patients but the risk of malignant change is not entirely removed. Provided gene delivery to these areas can be shown to be safe then these patients have nothing to lose from prophylactic treatment with a normal APC transgene. They are already under surveillance and might be ready to undergo trials of oral or endoscopic or enema gene therapy to reduce or delay their risk of cancer developing in these sites, while accepting that their risks will not be completely abolished by these treatments.
